Eli Lilly-Boehringer Ingelheim bags USFDA nod for Type 2 diabetes drugs Jardiance, Synjardy for children

Published On 2023-06-21 11:00 GMT   |   Update On 2023-06-21 11:01 GMT
Advertisement

United States: The U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly and partner Boehringer Ingelheim's drugs Jardiance and Synjardy to treat type 2 diabetes in children.

The drugs were approved as additions to diet and exercise to improve blood sugar control in children aged 10 years and above with type 2 diabetes, the most common form of the disease.

The approvals were based on a study that showed patients aged between 10 years and 17 years recorded lower average blood sugar compared with placebo when treated with empagliflozin - the active ingredient in the two drugs.

Advertisement

Empagliflozin, which works by increasing the excretion of glucose in urine, offers an alternative to pediatric patients for whom diabetes drug metformin has been the only oral treatment.

Jardiance and Synjardy were first approved by the FDA in 2014 and 2015, respectively, for treating type 2 diabetes in adults.

Read also: Eli Lilly-Boehringer's Jardiance for children with type 2 diabetes accepted by USFDA

In type 2 diabetes, the body does not make or use insulin normally, leading to high levels of glucose in the blood.

Eli Lilly shares were largely flat in extended trading.

Read also: USFDA accepts supplemental New Drug Application for Jardiance for adults with chronic kidney disease: Eli Lilly




Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News